Literature DB >> 32169796

Johannesburg Cancer Study (JCS): contribution to knowledge and opportunities arising from 20 years of data collection in an African setting.

Wenlong Carl Chen1, Elvira Singh2, Mazvita Muchengeti3, Debbie Bradshaw4, Christopher G Mathew5, Chantal Babb de Villiers6, Cathryn M Lewis7, Tim Waterboer8, Robert Newton9, Freddy Sitas10.   

Abstract

The Johannesburg Cancer Study (JCS) aims were to examine whether cancer risk factors identified in Western countries applied to black patients in Johannesburg, South Africa and to understand the impact of HIV on cancer risk, with a view to identifying previously unrecognised HIV associated cancers. A total of 24 971 black patients with an incident histologically proven (>95%) cancer of any type were enrolled between 1995-2016. Response rates were >90%. Patients provided informed consent, lifestyle and demographic information using a structured questionnaire; 19 351 provided a serum sample and 18 972 a whole blood sample for genomic analyses. This is currently the largest cancer epidemiological biobank in Africa. JCS uses a cancer case-control method; controls being cancer types unrelated to exposures of interest. Published results show the importance of HIV in several cancers known to be infection associated e.g. Kaposi sarcoma (OR = 1683; CI = 595-5194) in those with high Kaposi-sarcoma-associated-herpesvirus titres; no effect of HIV on lung or liver cancer-in the latter showing a strong association with HBVDNA, sAg and c positivity (OR = 47; CI = 21-104). Comparable data to higher-income country studies include lung cancer ORs in relation to smoking (15+g tobacco/day) (ORMales = 37; CI = 21-67, ORFemales = 18.5; CI = 8-45) and associations between alcohol and oesophageal cancer in smokers (ORM&F = 4.4; CI = 3-6). Relationship between hormonal contraception declined to null 10 or more years after stopping for breast (OR = 1.1; CI = 0.9-1.4) and cervical cancer (OR = 1.0;CI = 0.8-1.2), and protective effects shown, five or more years after stopping for ovarian (OR = 0.6; CI = 0.4-1) and endometrial cancer (OR = 0.4; CI = 0.2-0.9). Preferential access is based on data requests promoting data pooling, equal collaborative opportunities and enhancement of research capacity in South Africa. The JCS is a practical and valid design in otherwise logistically difficult settings.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer Biosample; Cancer cohort; JCS; Johannesburg Cancer Study

Mesh:

Year:  2020        PMID: 32169796     DOI: 10.1016/j.canep.2020.101701

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.984


  4 in total

1.  Skin cancer risk factors among Black South Africans-The Johannesburg Cancer Study, 1995-2016.

Authors:  Babongile C Ndlovu; Mazvita Sengayi-Muchengeti; Caradee Y Wright; Wenlong C Chen; Lazarus Kuonza; Elvira Singh
Journal:  Immun Inflamm Dis       Date:  2022-07

2.  HPV types 16/18 L1 E6 and E7 proteins seropositivity and cervical cancer risk in HIV-positive and HIV-negative black South African women.

Authors:  Mwiza Gideon Singini; Elvira Singh; Debbie Bradshaw; Wenlong Carl Chen; Melitah Motlhale; Abram Bunya Kamiza; Chantal Babb de Villiers; Mazvita Muchengeti; Christopher G Mathew; Robert Newton; Noemi Bender; Tim Waterboer; Freddy Sitas
Journal:  Infect Agent Cancer       Date:  2022-03-29       Impact factor: 2.965

3.  Esophageal Cancer Genomics in Africa: Recommendations for Future Research.

Authors:  Hannah Simba; Gerard Tromp; Vikash Sewram; Christopher G Mathew; Wenlong C Chen; Helena Kuivaniemi
Journal:  Front Genet       Date:  2022-03-25       Impact factor: 4.599

4.  Ranking lifestyle risk factors for cervical cancer among Black women: A case-control study from Johannesburg, South Africa.

Authors:  Mwiza Gideon Singini; Freddy Sitas; Debbie Bradshaw; Wenlong Carl Chen; Melitah Motlhale; Abram Bunya Kamiza; Chantal Babb de Villiers; Cathryn M Lewis; Christopher G Mathew; Tim Waterboer; Robert Newton; Mazvita Muchengeti; Elvira Singh
Journal:  PLoS One       Date:  2021-12-08       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.